Consensus ARS Pharmaceuticals, Inc.

Equities

SPRY

US82835W1080

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
8.7 ^USD	+1.16%		+2.35%	+58.76%

Apr. 18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT
Apr. 18	ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	MT

Evolution of the average Target Price on ARS Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d38f.QwLMU7FB45RDxs2aUq_0LTH_dOddzh8iB31-T4HNcv4.DFj8a9RzsNsQsp3dKMmWSQCMAtUuqUtOUggSfO2LPYwhT58Y5xKL1Q6rjA~38a80cb2b0dbc763f8cc12eb15001158

Analyst Recommendations on ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
ARS Pharmaceuticals Insider Sold Shares Worth $928,005, According to a Recent SEC Filing	Apr. 18	MT
Ars Pharmaceuticals Insider Sold Shares Worth $927,735, According to a Recent SEC Filing	Apr. 10	MT
Leerink Partners Upgrades ARS Pharmaceuticals to Outperform From Market Perform, Raises Price Target to $18 From $6	Mar. 05	MT
William Blair Upgrades ARS Pharmaceuticals to Outperform From Market Perform	Feb. 20	MT
Wedbush Raises ARS Pharmaceuticals' PT to $19 From $13 After Model Adjustments, Keeps Outperform Rating	Feb. 06	MT
Wedbush Raises ARS Pharmaceuticals' PT to $13 From $5, Says Market Opportunity Intact; Maintains Outperform Rating	Nov. 13	MT
Wall Street Set to Open Wednesday Trading Higher as Investors Await Fed Decision on Interest Rates	23-09-20	MT
US Futures Rise Modestly Pre-Bell as Investors Await Fed Rate Decision	23-09-20	MT
Rate Hike Pause Hopes Boost Exchange-Traded Funds, Equity Futures Premarket Wednesday	23-09-20	MT
William Blair Downgrades ARS Pharmaceuticals to Market Perform From Outperform	23-09-20	MT
Wedbush Trims ARS Pharmaceuticals' PT to $15 From $17, Adjusts US, EU Launch Estimates, Lowers Peak Penetration for neffy/Anaphylaxis in US; Keeps Outperform Rating	23-06-21	MT
Wedbush Initiates ARS Pharmaceuticals at Outperform With $10 PT, Says Neffy Intranasal Spray Set to Shake Up Epinephrine Market	23-01-31	MT
William Blair Initiates ARS Pharmaceuticals With Outperform	23-01-04	MT
SVB Securities Initiates ARS Pharmaceuticals With Outperform Rating, Price Target is $14	22-12-13	MT
Stifel Adjusts Price Target on Silverback Therapeutics to $5 From $6, Reiterates Hold Rating	22-05-16	MT
Goldman Sachs Downgrades Silverback Therapeutics to Neutral From Buy, Adjusts Price Target to $3.50 From $25	22-04-04	MT
JonesTrading Downgrades Silverback Therapeutics to Hold From Buy	22-04-01	MT
SVB Leerink Downgrades Silverback Therapeutics to Market Perform from Outperform, Adjusts Price Target to $1.80 from $25	22-04-01	MT
HC Wainwright Downgrades Silverback Therapeutics to Neutral from Buy	22-04-01	MT
Stifel Downgrades Silverback Therapeutics to Hold from Buy, Adjusts Price Target to $6 from $32	22-04-01	MT
SVB Leerink Adjusts Silverback Therapeutics' Price Target to $25 From $42, Keeps Outperform Rating	21-11-12	MT
SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Silverback Therapeutics' Price Target to $49 from $46, Keeps Outperform Rating	21-08-16	MT
SILVERBACK THERAPEUTICS : JonesTrading Starts Silverback Therapeutics at Buy With $50 Price Target	21-05-27	MT
SILVERBACK THERAPEUTICS : SVB Leerink Adjusts Price Target on Silverback Therapeutics to $46 From $49, Maintains Outperform Rating	21-05-24	MT